Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 4, 2005, Pages 310-313

  Mugellini, Amedeo ^a   Rinaldi, Andrea ^a   Zoppi, Annalisa ^a   Lazzari, Pierangelo ^a   Fogari, Elena ^a   Corradi, Luca ^a   Fogari, Roberto ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Atenolol; Diabetes; Manidipine; Platelet aggregability; Systolic hypertension

Indexed keywords

ADENOSINE DIPHOSPHATE; ATENOLOL; CITRATE SODIUM; COLLAGEN; MANIDIPINE; PLACEBO; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC HYPERTENSION; THROMBOCYTE AGGREGATION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ATENOLOL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; PLATELET AGGREGATION;

EID: 15744374081     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000155387.49103.87     Document Type: Article

References (41)

1. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens. 1990;8:393-405.
2. Mehler PS, Jeffers BW, Estacio R, et al. Association of hypertension and complications in non-insulin dependent diabetes mellitus. Am J Hypertens. 1997;10:152-161.
3. Tuomilehto J, Rastenyte D, Birkenhager WH, et al for the Systolic Hypertension In Europe. (Syst-Eur) Trial Investigator. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
4. Staessen JA, Fagard R, Thijs L, et al for the Systolic Hypertension (Syst-Eur) in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
5. Wang JS, Staessen JA, Gong L, et al, for The Systolic Hypertension in China (Syst-China) Trial Investigators. Subgroup analysis of the placebo-controlled Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 2000;160:149-150.
6. Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
7. Sowers JR. Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Am J Cardiol. 1997;79:24-28.
8. Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med. 1992;152:1573-1584.
9. Berkels R, Klaus W, Boller M, et al. The calcium modulator nifedipine stimulates endothelial NO release in therapeutic concentrations. Pharm Plarmacol Lett. 1986;6:75-78.
10. Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium dependent vasodilation in essential hypertensive patients. Hypertension. 1997;30:1606-1612.
11. Ono H, Himura M. Effect of Ca-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil on platelet aggregation in vitro. Drug Res. 1981;31:1131-1134.
12. Zannad F, Voisin P, Sadoul N. Effects de la nicardipine intravenieuse sur la pression arterielle, l'hemoreologie et le function plaquettaries dans l'hypertension arterielle. Arch Mal Coeur. 1987;6:844-850.
13. Berkels R, Klauis W, Boller M, et al. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb Haemost. 1994;72:309-312.
14. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc Pharmacol. 1995;25:87-89.
15. Fogari R, Lusardi P, Zoppi A, et al. Effect of nicardipine SR on platelet aggregation in elderly hypertensive patients with type II diabetes mellitus. High Blood Press. 1997;6:144-147.
16. Hernandez R, Guerrero-Pajuelo J, Pacheco B. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther. 1999;37:323-331.
17. Mazzanti I, Mutus B. Diabetes-induced alterations in platelet metabolism. Clin Biochem. 1997;30:509-515.
18. Andren L, Dotevall A, Eggertsen R, et al. Effects of diltiazem on hemodynamics and platelet function in diabetic patients with essential hypertension. J Cardiovasc Pharmacol. 1988;12(Suppl.6):S184.
19. Klauser R, Speiser P, Gisinger C, et al. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J Cardiovasc Pharmacol 1990;15(Suppl 1):S93-S96.
20. Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension. 2003;42:1-7.
21. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977;49:185-196.
22. Winther K, Knudsen JB, Gormsen J, et al. Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmac. 1986;29:561-564.
23. Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol. 1991;18(Suppl.4):S29-S34.
24. Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens. 1994;8:273-278.
25. Srivastava KC. Influence of some beta-blockers (pindolol, atenolol, timolol and metoprolol) on aggregation and arachidonic acid metabolism in human platelets. Postgrad Leucotrien Med. 1987;29:79-84.
26. Smith A, McPherson J, Taylor M, et al. Pro-hemorragic effects of calcium antagonists:a comparison of isradipine and atenolol on ex-vivo platelet function in hypertensive patients. J Hum Hypertens. 1997;11:783-788.
27. Cheer SM, McClellan K. Manidipine. Drugs. 2001;61:1777-1799.
28. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178-195.
29. Senn SJ. Cross-over Trials in Clinical Research. New York: Wiley, 1993.
30. Rosado JA, Sage SO. Platelet signaling: calcium. In: Gresele G, Page C, Fuster V, Vermylen J, eds. Platelets in Thrombotic and Non-thrombotic Disorders. Cambridge, UK: Cambridge University Press, 2002, p 260-271.
31. Jones CR, Pasanishi F, Elliot HL, et al. Effects of verapamil and nisoldipine on human platelets:in vivo and in vitro studies. Br J Clin Pharmacol. 1985;20:191-196.
32. Greer JA, Walker JJ, McLaren M, et al. Inhibition of whole platelet aggregation by nicardipine and synergism with prostacyclin in vivo. Thromb Res. 1986;41:509-518.
33. McIntyre DE, Show AM. Phospholip-induced human platelet activation. Effects of calcium channel blockers and calcium chelators. Thromb Res. 1983;31:833-844.
34. Metha P, Metha J, Ostrokowski N, et al. Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations. J Lab Clin Med. 1983;102:332-339.
35. Feinstein MB, Fiekers J, Fraser C. An analysis of the mechanism of local anesthetic inhibition of platelet aggregation and secretion. J Pharmacol Exp Ther. 1976;3:215-228.
36. Moore JB, Fuller BL, Falotico R, et al. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers. Thromb Res. 1985;40:401-411.
37. Henry PD. Antiatherogenic effects of calcium channel blockers:possible mechanisms of action. Cardiovasc Drugs Ther. 1990;4:1015-1020.
38. Winther K, Klysner R, Geisler A, et al. Characterisation of human platelet beta-adrenoceptors. Thromb Res. 1985;40:757-767.
39. Dash D, Rao K. Effect of propranolol on platelet signal tranduction. Biochem J. 1995;309:99-104.
40. Gasowski J, Birkenhager WH, Staessen JA, et al. Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur). Trial. Cardiovasc Drugs Ther. 2000;14:49-53.
41. Safar M, Thijs L, Staessen JA. Etude Syst-Eur: analyse des benefices de la nitrendipine chez le patients diabetiques de type 2 hypertendus. Arch Mal Coeur. 2003;96:768-771.